HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
All
Press Release
News Update
Quarterly update
Total
86
16
Press Release
NeoImmuneTech Appoints Gene Namgoong as Chief Operating Officer
2020-01-30
15
Press Release
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
2020-01-28
14
Press Release
NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
2019-12-11
13
Press Release
NeoImmuneTech Announces Formation of Scientific Advisory Board to Support Development of its Immunotherapeutics Portfolio
2019-11-13
12
Press Release
NeoImmuneTech Appoints Dr. Samuel Zhang as Chief Business Officer
2019-06-04
11
Press Release
NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors
2019-05-24
10
Press Release
Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7
TM
with Merck’s KEYTRUDA
®
in Triple-Negative Breast Cancer
2019-04-26
9
Press Release
FDA Grants Orphan Drug Designation Status to NeoImmuneTech’s Hyleukin-7 for Idiopathic CD4+ Lymphocytopenia Treatment
2019-04-16
8
Press Release
NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
2019-04-03
7
Press Release
NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7
TM
in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers
2019-01-16
<<
<
6
7
8
9
Search